Multiple Sclerosis
Group leader
Luisa María Villar Guimerans
luisamaria.villar(ELIMINAR)@salud.madrid.org
Tlf.: 0034 913368029
Principal Investigator
- Eulalia Rodríguez Martín
Collaborating Staff
- María Mercedes Espiño Martínez
- Ernesto Roldán Santiago
- Lucienne Costa-Frossard França
- Susana Sainz de la Maza Cantero
- Enric Monreal Laguillo
- José Ignacio Fernández Velasco
- Noelia Villarrubia Migallón
- Roberto Pariente Rodríguez
- Alexander Rodero Romero
- Juan Luis Chico Garcia
- Fernando Rodríguez Jorge
- Paula Batres Faba
- Raquel Sainz Amo
- José Luis Veiga González
- María Eugenia Martín Villasevil
Group leader
Luisa María Villar Guimerans
luisamaria.villar(ELIMINAR)@salud.madrid.org
Tlf.: 0034 913368029
Principal Investigator
- Eulalia Rodríguez Martín
Collaborating Staff
- María Mercedes Espiño Martínez
- Ernesto Roldán Santiago
- Lucienne Costa-Frossard França
- Susana Sainz de la Maza Cantero
- Enric Monreal Laguillo
- José Ignacio Fernández Velasco
- Noelia Villarrubia Migallón
- Roberto Pariente Rodríguez
- Alexander Rodero Romero
- Juan Luis Chico Garcia
- Fernando Rodríguez Jorge
- Paula Batres Faba
- Raquel Sainz Amo
- José Luis Veiga González
- María Eugenia Martín Villasevil
Strategic Objectives
- Deepen the study of the pathophysiological mechanisms of MS in order to identify new therapeutic targets for the disease and contribute to the personalized treatment of patients.
- Study the mechanisms associated with progressive forms of the disease, for which there is only one currently approved treatment.
- Identify immunological factors that early predict the risk of progression in MS in order to establish personalized therapy for this disease.
- Evaluate biomarkers of response to treatment and identify patients at risk of serious side effects.
- Study environmental factors that play a role in the course of the disease, to see if modifying them could have a beneficial effect on patients.
Research Lines
- Search for biomarkers that identify the best benefit/risk profile for different biologic therapies in MS.
- Search for biomarkers to identify the risk of progression in MS.
- Immunological mechanisms that are associated with primarily progressive forms of MS.
- Association of antibodies to Epstein-Barr virus and clinical and immunologic phenotype in MS.
- Study of the response to vaccines against SARS-CoV-2 in MS.
- Study of pathological mechanisms in MS.
Location
Laboratory:
Immunology Service. 1st floor left.
Clinical Unit:
Neurology Service: 2nd floor center.
Ramón y Cajal University Hospital
Keywords
multiple sclerosis (MS), biomarkers, immunological mechanisms, B cells, antibodies.